•4DMT reports new phase 2b gene therapy data for wet AMD•Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study•Claris Bio raises $118M to advance first-ever LSCD therapy•Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt•Pediatric cataract surgery carries greater endophthalmitis risk•4DMT reports new phase 2b gene therapy data for wet AMD•Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study•Claris Bio raises $118M to advance first-ever LSCD therapy•Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt•Pediatric cataract surgery carries greater endophthalmitis risk
HEADLINES
RESEARCH
NSAID use may lower AMD risk
FEATURED
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
![[object Object]](/_next/image/?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F51cpf7jm%2Fproduction%2F0fbac34bad6d09f82e441f0027ebe861bc590ab8-1200x628.png%3Fw%3D2400%26q%3D100%26fit%3Dfill%26auto%3Dformat&w=3840&q=75)
